SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4xey'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1FDU_D_ESTD352_1 (17-BETA-HYDROXYSTERO ID DEHYDROGENASE)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	VAL B 323 GLY B 322 LEU B 320 GLU B 311	None	1.03A	1fduD-4xeyB: undetectable	1fduD-4xeyB: 20.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 MET B 309 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.81A	1iepA-4xeyB: 35.1	1iepA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 MET B 309 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.67A	1iepA-4xeyB: 35.1	1iepA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LYS B 290 VAL B 308 VAL B 318 ILE B 332	1N1 B 601 (-4.6A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.85A	1iepA-4xeyB: 35.1	1iepA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	VAL B 308 VAL B 318 ILE B 332 MET B 337	None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None	0.55A	1iepA-4xeyB: 35.1	1iepA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.5A)	0.95A	1iepB-4xeyB: 29.0	1iepB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.5A)	0.85A	1iepB-4xeyB: 29.0	1iepB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 7	LYS B 290 VAL B 308 VAL B 318 ILE B 332	1N1 B 601 (-4.6A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.53A	1iepB-4xeyB: 29.0	1iepB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 7	VAL B 308 ILE B 332 MET B 337 LEU B 389	None 1N1 B 601 (-4.1A) None 1N1 B 601 (-4.3A)	0.62A	1iepB-4xeyB: 29.0	1iepB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 7	VAL B 308 VAL B 318 ILE B 332 LEU B 389	None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-4.3A)	0.66A	1iepB-4xeyB: 29.0	1iepB-4xeyB: 71.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1JLF_A_NVPA999_1 (HIV-1 RT A-CHAIN HIV-1 RT B-CHAIN)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 8	LEU B 346 VAL B 390 CYH B 388 GLY B 340	None None None 1N1 B 601 (-3.5A)	1.02A	1jlfA-4xeyB: undetectable 1jlfB-4xeyB: undetectable	1jlfA-4xeyB: 20.51 1jlfB-4xeyB: 22.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1M17_A_AQ4A999_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	LEU B 267 ALA B 288 LYS B 290 THR B 334 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.42A	1m17A-4xeyB: 28.0	1m17A-4xeyB: 28.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_A_STIA3_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	LEU B 267 VAL B 275 ILE B 312 VAL B 318 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) None 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.88A	1opjA-4xeyB: 34.0	1opjA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_A_STIA3_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.80A	1opjA-4xeyB: 34.0	1opjA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_A_STIA3_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.64A	1opjA-4xeyB: 34.0	1opjA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_B_STIB4_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 THR B 334 PHE B 336 GLY B 340 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.5A)	0.87A	1opjB-4xeyB: 27.9	1opjB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_B_STIB4_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LEU B 267 LYS B 290 VAL B 308 ILE B 332	1N1 B 601 (-3.7A) 1N1 B 601 (-4.6A) None 1N1 B 601 (-4.1A)	0.91A	1opjB-4xeyB: 27.9	1opjB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_B_STIB4_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LEU B 267 VAL B 308 ILE B 332 MET B 337	1N1 B 601 (-3.7A) None 1N1 B 601 (-4.1A) None	0.64A	1opjB-4xeyB: 27.9	1opjB-4xeyB: 71.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1T46_A_STIA3_1 (HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 VAL B 318 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.78A	1t46A-4xeyB: 26.6	1t46A-4xeyB: 29.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XBB_A_STIA1_1 (TYROSINE-PROTEIN KINASE SYK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 9	LEU B 267 VAL B 275 ALA B 288 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.31A	1xbbA-4xeyB: 29.5	1xbbA-4xeyB: 33.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	ALA B 288 THR B 334 GLY B 340 LEU B 343 ASP B 344 LEU B 389	1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None None 1N1 B 601 (-4.3A)	0.87A	1xkkA-4xeyB: 26.3	1xkkA-4xeyB: 29.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	THR B 334 GLY B 340 LEU B 343 ASP B 344 ARG B 347 LEU B 389	1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None None None 1N1 B 601 (-4.3A)	0.68A	1xkkA-4xeyB: 26.3	1xkkA-4xeyB: 29.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	ALA B 288 LYS B 290 MET B 309 VAL B 318 ILE B 332 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.65A	2gqgA-4xeyB: 32.2	2gqgA-4xeyB: 71.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	LEU B 267 ALA B 288 MET B 309 VAL B 318 ILE B 332 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.52A	2gqgA-4xeyB: 32.2	2gqgA-4xeyB: 71.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 ILE B 332 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.40A	2gqgB-4xeyB: 38.3	2gqgB-4xeyB: 71.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HDN_L_TACL6888_1 (ELONGATION FACTOR EF-TU)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	SER B 439 VAL B 441 SER B 436 ASP B 410	None	1.16A	2hdnJ-4xeyB: undetectable 2hdnK-4xeyB: undetectable 2hdnL-4xeyB: undetectable	2hdnJ-4xeyB: 22.40 2hdnK-4xeyB: 8.82 2hdnL-4xeyB: 22.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_A_STIA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.89A	2hyyA-4xeyB: 35.3	2hyyA-4xeyB: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.78A	2hyyB-4xeyB: 35.8	2hyyB-4xeyB: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LEU B 267 LYS B 290 VAL B 318 ILE B 332	1N1 B 601 (-3.7A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.91A	2hyyB-4xeyB: 35.8	2hyyB-4xeyB: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LEU B 267 VAL B 308 ILE B 332 MET B 337	1N1 B 601 (-3.7A) None 1N1 B 601 (-4.1A) None	0.68A	2hyyB-4xeyB: 35.8	2hyyB-4xeyB: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LEU B 267 VAL B 308 VAL B 318 ILE B 332	1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.59A	2hyyB-4xeyB: 35.8	2hyyB-4xeyB: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_C_STIC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 ILE B 312 VAL B 318 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.69A	2hyyC-4xeyB: 36.1	2hyyC-4xeyB: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_C_STIC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 6	LEU B 267 LYS B 290 VAL B 308 MET B 309 ILE B 332	1N1 B 601 (-3.7A) 1N1 B 601 (-4.6A) None 1N1 B 601 (-3.7A) 1N1 B 601 (-4.1A)	0.88A	2hyyC-4xeyB: 36.1	2hyyC-4xeyB: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_C_STIC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 6	LEU B 267 VAL B 308 MET B 309 ILE B 332 MET B 337	1N1 B 601 (-3.7A) None 1N1 B 601 (-3.7A) 1N1 B 601 (-4.1A) None	0.61A	2hyyC-4xeyB: 36.1	2hyyC-4xeyB: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_D_STID600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 ILE B 332 THR B 334 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.83A	2hyyD-4xeyB: 35.4	2hyyD-4xeyB: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITO_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 ALA B 288 LYS B 290 MET B 309 THR B 334 GLY B 340	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A)	0.67A	2itoA-4xeyB: 26.8	2itoA-4xeyB: 28.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITO_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	LEU B 267 ALA B 288 LYS B 290 THR B 334 GLY B 340 ASP B 344 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.63A	2itoA-4xeyB: 26.8	2itoA-4xeyB: 28.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 309 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.69A	2ityA-4xeyB: 26.7	2ityA-4xeyB: 28.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITZ_A_IREA2021_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 309 THR B 334 GLY B 340	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A)	0.61A	2itzA-4xeyB: 26.3	2itzA-4xeyB: 28.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITZ_A_IREA2021_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 THR B 334 GLY B 340 ASP B 344 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.68A	2itzA-4xeyB: 26.3	2itzA-4xeyB: 28.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2OIQ_A_STIA1001_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 332 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.59A	2oiqA-4xeyB: 32.6	2oiqA-4xeyB: 36.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PL0_A_STIA200_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 MET B 309 VAL B 318 ILE B 332 THR B 334 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.83A	2pl0A-4xeyB: 26.1	2pl0A-4xeyB: 37.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PL0_A_STIA200_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	VAL B 275 ALA B 288 LYS B 290 MET B 309 VAL B 318 ILE B 332 THR B 334	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A)	0.76A	2pl0A-4xeyB: 26.1	2pl0A-4xeyB: 37.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PL0_A_STIA200_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	VAL B 275 ALA B 288 MET B 309 VAL B 318 ILE B 332 THR B 334 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A)	0.83A	2pl0A-4xeyB: 26.1	2pl0A-4xeyB: 37.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2XP2_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.41A	2xp2A-4xeyB: 13.4	2xp2A-4xeyB: 31.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y6O_A_1N1A1892_1 (EPHRIN TYPE-A RECEPTOR 4)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 LYS B 290 MET B 309 ILE B 332 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.61A	2y6oA-4xeyB: 28.0	2y6oA-4xeyB: 31.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_C_B49C1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 10	VAL B 275 ALA B 288 MET B 337 GLY B 340 ASP B 344 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.52A	2y7jC-4xeyB: 19.8	2y7jC-4xeyB: 26.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_D_B49D1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 10	VAL B 275 ALA B 288 MET B 337 GLY B 340 ASP B 344 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.66A	2y7jD-4xeyB: 25.8	2y7jD-4xeyB: 26.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	11 / 12	LEU B 267 ALA B 288 LYS B 290 MET B 309 VAL B 318 ILE B 332 THR B 334 MET B 337 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.58A	2zvaA-4xeyB: 33.3	2zvaA-4xeyB: 34.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 10	LEU B 267 ALA B 288 LYS B 290 VAL B 318 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.59A	3aoxA-4xeyB: 25.2	3aoxA-4xeyB: 32.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	VAL B 275 ALA B 288 LEU B 320 THR B 334 GLY B 340 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.63A	3bbtB-4xeyB: 25.0	3bbtB-4xeyB: 29.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 GLU B 277 ALA B 288 LYS B 290 VAL B 318 PHE B 336 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.83A	3c7qA-4xeyB: 30.8	3c7qA-4xeyB: 32.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 10	LEU B 267 VAL B 275 LYS B 290 LYS B 304 ILE B 332 VAL B 398	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-4.6A) None 1N1 B 601 (-4.1A) None	1.16A	3cs9A-4xeyB: 35.8	3cs9A-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 10	LEU B 267 VAL B 275 LYS B 290 VAL B 318 ILE B 332 VAL B 398	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None	0.83A	3cs9A-4xeyB: 35.8	3cs9A-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 10	LEU B 267 VAL B 275 LYS B 304 ILE B 332 PHE B 336 VAL B 398	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) None 1N1 B 601 (-4.1A) 1N1 B 601 ( 4.2A) None	0.98A	3cs9A-4xeyB: 35.8	3cs9A-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 10	LEU B 267 VAL B 275 VAL B 318 ILE B 332 PHE B 336 VAL B 398	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 ( 4.2A) None	0.68A	3cs9A-4xeyB: 35.8	3cs9A-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	ALA B 288 VAL B 308 MET B 309 LEU B 317 THR B 334 GLY B 340 HIS B 380 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.52A	3cs9A-4xeyB: 35.8	3cs9A-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 308 MET B 309 ILE B 312 LEU B 317 GLY B 340 HIS B 380 LEU B 389 ALA B 399	None 1N1 B 601 (-3.7A) None None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.66A	3cs9A-4xeyB: 35.8	3cs9A-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	ALA B 288 VAL B 308 MET B 309 ILE B 312 LEU B 317 GLY B 340 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None None 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A)	0.68A	3cs9B-4xeyB: 30.5	3cs9B-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	ALA B 288 VAL B 308 MET B 309 LEU B 317 THR B 334 GLY B 340 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A)	0.49A	3cs9B-4xeyB: 30.5	3cs9B-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 9	LEU B 267 VAL B 275 LYS B 290 VAL B 318 ILE B 332 PHE B 378 VAL B 398	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None None	0.81A	3cs9B-4xeyB: 30.5	3cs9B-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 9	LEU B 267 VAL B 275 VAL B 318 ILE B 332 PHE B 378 LEU B 389 VAL B 398	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None 1N1 B 601 (-4.3A) None	0.67A	3cs9B-4xeyB: 30.5	3cs9B-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	ALA B 288 VAL B 308 MET B 309 ILE B 312 LEU B 317 THR B 334 PHE B 336 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A)	0.72A	3cs9C-4xeyB: 29.2	3cs9C-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	VAL B 308 MET B 309 ILE B 312 LEU B 317 THR B 334 PHE B 378	None 1N1 B 601 (-3.7A) None None 1N1 B 601 (-3.3A) None	1.48A	3cs9C-4xeyB: 29.2	3cs9C-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 LYS B 290 VAL B 318 ILE B 332 VAL B 398	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None	0.83A	3cs9C-4xeyB: 29.2	3cs9C-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 VAL B 318 ILE B 332 MET B 337 VAL B 398	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None None	0.67A	3cs9C-4xeyB: 29.2	3cs9C-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	ALA B 288 VAL B 308 MET B 309 ILE B 312 LEU B 317 PHE B 336 GLY B 340 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None None 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A)	0.68A	3cs9D-4xeyB: 33.6	3cs9D-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	ALA B 288 VAL B 308 MET B 309 LEU B 317 THR B 334 PHE B 336 GLY B 340 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A)	0.52A	3cs9D-4xeyB: 33.6	3cs9D-4xeyB: 74.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0F_B_B49B9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 10	LEU B 267 VAL B 275 ALA B 288 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.71A	3g0fB-4xeyB: 30.6	3g0fB-4xeyB: 30.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_A_1N1A1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 ILE B 332 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.41A	3g5dA-4xeyB: 27.3	3g5dA-4xeyB: 36.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_B_1N1B1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.51A	3g5dB-4xeyB: 27.4	3g5dB-4xeyB: 36.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GVU_A_STIA1001_1 (TYROSINE-PROTEIN KINASE ABL2)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 THR B 334 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.78A	3gvuA-4xeyB: 29.1	3gvuA-4xeyB: 64.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 MET B 309 ILE B 312 LEU B 317 HIS B 380 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None None None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.63A	3ik3A-4xeyB: 36.3	3ik3A-4xeyB: 92.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_A_0LIA1_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 7	LEU B 267 VAL B 308 ILE B 332 MET B 337	1N1 B 601 (-3.7A) None 1N1 B 601 (-4.1A) None	0.60A	3ik3A-4xeyB: 36.3	3ik3A-4xeyB: 92.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 MET B 309 ILE B 312 LEU B 317 HIS B 380 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None None None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.59A	3ik3B-4xeyB: 30.1	3ik3B-4xeyB: 92.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_B_0LIB2_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 7	LEU B 267 VAL B 308 ILE B 332 MET B 337	1N1 B 601 (-3.7A) None 1N1 B 601 (-4.1A) None	0.63A	3ik3B-4xeyB: 30.1	3ik3B-4xeyB: 92.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K54_A_1N1A1_1 (TYROSINE-PROTEIN KINASE BTK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 ALA B 288 LYS B 290 MET B 309 VAL B 318 ILE B 332 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.55A	3k54A-4xeyB: 26.7	3k54A-4xeyB: 36.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_A_STIA2_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.79A	3k5vA-4xeyB: 34.2	3k5vA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_A_STIA2_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LEU B 267 LYS B 290 VAL B 318 ILE B 332	1N1 B 601 (-3.7A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.82A	3k5vA-4xeyB: 34.2	3k5vA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_B_STIB2_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.77A	3k5vB-4xeyB: 34.2	3k5vB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_B_STIB2_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LEU B 267 LYS B 290 VAL B 318 ILE B 332	1N1 B 601 (-3.7A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.91A	3k5vB-4xeyB: 34.2	3k5vB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_A_B49A1_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 11	ALA B 288 LYS B 290 VAL B 318 PHE B 336 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.79A	3miyA-4xeyB: 26.2	3miyA-4xeyB: 30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_B_B49B2_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	ALA B 288 LYS B 290 PHE B 336 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.59A	3miyB-4xeyB: 27.2	3miyB-4xeyB: 30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.86A	3ms9A-4xeyB: 35.1	3ms9A-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LYS B 290 VAL B 308 VAL B 318 ILE B 332	1N1 B 601 (-4.6A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.73A	3ms9A-4xeyB: 35.1	3ms9A-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	VAL B 308 VAL B 318 ILE B 332 MET B 337	None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None	0.51A	3ms9A-4xeyB: 35.1	3ms9A-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.86A	3ms9B-4xeyB: 35.4	3ms9B-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.86A	3mssA-4xeyB: 35.4	3mssA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LYS B 290 VAL B 308 VAL B 318 ILE B 332	1N1 B 601 (-4.6A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.74A	3mssA-4xeyB: 35.4	3mssA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	VAL B 308 VAL B 318 ILE B 332 MET B 337	None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None	0.54A	3mssA-4xeyB: 35.4	3mssA-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 MET B 309 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.46A	3mssB-4xeyB: 29.7	3mssB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	VAL B 275 ALA B 288 MET B 309 THR B 334 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.66A	3mssB-4xeyB: 29.7	3mssB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 7	LYS B 290 VAL B 308 VAL B 318 ILE B 332	1N1 B 601 (-4.6A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.82A	3mssB-4xeyB: 29.7	3mssB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 7	VAL B 308 VAL B 318 ILE B 332 MET B 337	None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None	0.55A	3mssB-4xeyB: 29.7	3mssB-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.87A	3mssC-4xeyB: 35.3	3mssC-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LYS B 290 VAL B 308 VAL B 318 ILE B 332	1N1 B 601 (-4.6A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.74A	3mssC-4xeyB: 35.3	3mssC-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	VAL B 308 VAL B 318 ILE B 332 MET B 337	None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None	0.57A	3mssC-4xeyB: 35.3	3mssC-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.74A	3mssD-4xeyB: 35.4	3mssD-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.91A	3mssD-4xeyB: 35.4	3mssD-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 6	VAL B 275 LYS B 290 VAL B 308 VAL B 318 ILE B 332	1N1 B 601 ( 4.9A) 1N1 B 601 (-4.6A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.75A	3mssD-4xeyB: 35.4	3mssD-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 6	VAL B 275 VAL B 308 VAL B 318 ILE B 332 MET B 337	1N1 B 601 ( 4.9A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) None	0.60A	3mssD-4xeyB: 35.4	3mssD-4xeyB: 71.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.51A	3octA-4xeyB: 13.6	3octA-4xeyB: 33.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 GLY B 340 GLU B 348 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	1.11A	3octA-4xeyB: 13.6	3octA-4xeyB: 33.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_A_STIA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.59A	3oezA-4xeyB: 24.4	3oezA-4xeyB: 36.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_A_STIA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 THR B 334 GLY B 340 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.59A	3oezA-4xeyB: 24.4	3oezA-4xeyB: 36.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_B_STIB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 LYS B 290 VAL B 308 MET B 309 ILE B 332 THR B 334 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) None 1N1 B 601 (-3.7A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.53A	3oezB-4xeyB: 25.1	3oezB-4xeyB: 36.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OKX_A_SAMA201_0 (YAEB-LIKE PROTEIN RPA0152)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 12	LEU B 160 HIS B 233 LEU B 184 SER B 222 LEU B 169	None	1.31A	3okxA-4xeyB: undetectable	3okxA-4xeyB: 17.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	ALA B 288 MET B 309 ILE B 312 LEU B 317 VAL B 318 THR B 334 GLY B 340 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None None 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A)	0.56A	3oxzA-4xeyB: 30.8	3oxzA-4xeyB: 93.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 9	LEU B 267 LYS B 290 VAL B 308 ILE B 332 VAL B 398	1N1 B 601 (-3.7A) 1N1 B 601 (-4.6A) None 1N1 B 601 (-4.1A) None	0.84A	3oxzA-4xeyB: 30.8	3oxzA-4xeyB: 93.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 308 ILE B 332 MET B 337 LEU B 389 VAL B 398	1N1 B 601 (-3.7A) None 1N1 B 601 (-4.1A) None 1N1 B 601 (-4.3A) None	0.50A	3oxzA-4xeyB: 30.8	3oxzA-4xeyB: 93.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_A_STIA3_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.57A	3pyyA-4xeyB: 29.9	3pyyA-4xeyB: 73.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_A_STIA3_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 THR B 334 PHE B 336 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A)	0.70A	3pyyA-4xeyB: 29.9	3pyyA-4xeyB: 73.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_A_STIA3_2 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LYS B 290 VAL B 308 VAL B 318 ILE B 332	1N1 B 601 (-4.6A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A)	0.97A	3pyyA-4xeyB: 29.9	3pyyA-4xeyB: 73.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_B_STIB4_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.72A	3pyyB-4xeyB: 31.0	3pyyB-4xeyB: 73.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_B_STIB4_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 THR B 334 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.66A	3pyyB-4xeyB: 31.0	3pyyB-4xeyB: 73.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_A_1N1A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.45A	3qlgA-4xeyB: 32.4	3qlgA-4xeyB: 36.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_A_1N1A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 LYS B 290 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.60A	3qlgA-4xeyB: 32.4	3qlgA-4xeyB: 36.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_B_1N1B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.44A	3qlgB-4xeyB: 27.3	3qlgB-4xeyB: 36.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.57A	3sxrA-4xeyB: 33.4	3sxrA-4xeyB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 VAL B 318 ILE B 332 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.44A	3sxrA-4xeyB: 33.4	3sxrA-4xeyB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.53A	3sxrB-4xeyB: 33.7	3sxrB-4xeyB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 VAL B 318 THR B 334 GLY B 340 LEU B 389 PHE B 401	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) None	0.86A	3sxrB-4xeyB: 33.7	3sxrB-4xeyB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	LEU B 267 ALA B 288 LYS B 290 VAL B 318 ILE B 332 THR B 334 PHE B 336 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.38A	3ue4A-4xeyB: 34.3	3ue4A-4xeyB: 93.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 VAL B 318 ILE B 332 THR B 334 PHE B 336 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.33A	3ue4B-4xeyB: 40.5	3ue4B-4xeyB: 93.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 337 GLY B 340 ASP B 344 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.61A	3ug2A-4xeyB: 28.5	3ug2A-4xeyB: 28.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZBF_A_VGHA3000_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 12	LEU B 267 ALA B 288 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.30A	3zbfA-4xeyB: 32.7	3zbfA-4xeyB: 33.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ZOS_A_0LIA1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	LEU B 267 ALA B 288 LYS B 290 THR B 334 HIS B 380 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.81A	3zosA-4xeyB: 29.8	3zosA-4xeyB: 29.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 VAL B 318 PHE B 336 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.74A	4ag8A-4xeyB: 26.2	4ag8A-4xeyB: 29.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 11	LEU B 267 ALA B 288 LYS B 290 PHE B 336 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.68A	4agdA-4xeyB: 30.9	4agdA-4xeyB: 32.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 11	LEU B 267 ALA B 288 VAL B 318 PHE B 336 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.56A	4agdA-4xeyB: 30.9	4agdA-4xeyB: 32.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 ALA B 288 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.67A	4anqA-4xeyB: 25.6	4anqA-4xeyB: 32.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.36A	4anqA-4xeyB: 25.6	4anqA-4xeyB: 32.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 ALA B 288 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.65A	4ansA-4xeyB: 25.5	4ansA-4xeyB: 32.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.34A	4ansA-4xeyB: 25.5	4ansA-4xeyB: 32.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4BKJ_B_STIB1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	VAL B 275 ALA B 288 MET B 309 THR B 334 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.88A	4bkjB-4xeyB: 30.1	4bkjB-4xeyB: 29.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_A_0LIA1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 LYS B 290 ILE B 332 THR B 334 HIS B 380 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.64A	4c8bA-4xeyB: 26.1	4c8bA-4xeyB: 24.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CSV_A_STIA1265_1 (SRC-ABL TYROSINE KINASE ANCESTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	VAL B 275 ALA B 288 MET B 309 THR B 334 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.56A	4csvA-4xeyB: 27.2	4csvA-4xeyB: 48.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4DF2_A_4CHA506_0 (NADPH DEHYDROGENASE)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	THR B 291 TYR B 276 HIS B 233 TYR B 331	None	1.16A	4df2A-4xeyB: undetectable	4df2A-4xeyB: 24.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 THR B 334 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.42A	4hjoA-4xeyB: 30.3	4hjoA-4xeyB: 28.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 309 VAL B 318 ILE B 332 THR B 334 GLY B 340	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A)	0.66A	4mxoA-4xeyB: 33.6	4mxoA-4xeyB: 36.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 VAL B 318 ILE B 332 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.47A	4mxoB-4xeyB: 33.1	4mxoB-4xeyB: 36.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 ALA B 288 LYS B 290 MET B 309 VAL B 318 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.73A	4mxxA-4xeyB: 33.2	4mxxA-4xeyB: 36.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 ALA B 288 LYS B 290 VAL B 318 ILE B 332 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.49A	4mxxA-4xeyB: 33.2	4mxxA-4xeyB: 36.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 VAL B 318 THR B 334 MET B 337 GLY B 340 LEU B 389 PHE B 401	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) None	0.57A	4mxxB-4xeyB: 32.5	4mxxB-4xeyB: 36.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXY_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	LEU B 267 VAL B 275 ALA B 288 VAL B 318 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.51A	4mxyB-4xeyB: 26.8	4mxyB-4xeyB: 35.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXZ_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	LEU B 267 VAL B 275 ALA B 288 VAL B 318 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.51A	4mxzB-4xeyB: 26.8	4mxzB-4xeyB: 35.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0U_A_ADNA501_1 (AURORA KINASE A)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	VAL B 275 ALA B 288 LYS B 290 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-4.3A)	0.52A	4o0uA-4xeyB: 8.2	4o0uA-4xeyB: 23.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 LYS B 290 VAL B 318 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.55A	4otwA-4xeyB: 25.7	4otwA-4xeyB: 27.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4R29_D_SAMD301_1 (UNCHARACTERIZED PROTEIN)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	3 / 3	ARG B 381 GLU B 300 TYR B 412	None	0.99A	4r29D-4xeyB: undetectable	4r29D-4xeyB: 19.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4R7I_A_STIA1001_1 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	VAL B 275 ALA B 288 LYS B 290 MET B 309 THR B 334 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A)	0.55A	4r7iA-4xeyB: 31.4	4r7iA-4xeyB: 31.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 LYS B 290 PHE B 336 MET B 337 ASN B 387 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.2A) None None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.73A	4twpA-4xeyB: 34.2	4twpA-4xeyB: 99.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 PHE B 336 MET B 337 GLY B 340 ASN B 387 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.58A	4twpA-4xeyB: 34.2	4twpA-4xeyB: 99.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 LYS B 290 PHE B 336 MET B 337 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.77A	4twpB-4xeyB: 33.1	4twpB-4xeyB: 99.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 PHE B 336 MET B 337 GLY B 340 ASN B 387 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.62A	4twpB-4xeyB: 33.1	4twpB-4xeyB: 99.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 LYS B 290 PHE B 336 MET B 337 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.76A	4twpB-4xeyB: 33.1	4twpB-4xeyB: 99.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 PHE B 336 MET B 337 GLY B 340 ASN B 387 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.58A	4twpB-4xeyB: 33.1	4twpB-4xeyB: 99.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TYJ_A_0LIA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	ALA B 288 MET B 309 ILE B 312 HIS B 380 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.61A	4tyjA-4xeyB: 32.4	4tyjA-4xeyB: 32.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 11	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 ASN B 387 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.53A	4u5jA-4xeyB: 34.3	4u5jA-4xeyB: 36.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.27A	4u5jB-4xeyB: 28.1	4u5jB-4xeyB: 36.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4UCI_A_ADNA2414_1 (RNA-DIRECTED RNA POLYMERASE L)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	GLU B 371 PHE B 505 PHE B 444 HIS B 509	None	1.25A	4uciA-4xeyB: undetectable	4uciA-4xeyB: 23.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_A_0LIA1776_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	ALA B 288 MET B 309 ILE B 312 LEU B 373 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None None None 1N1 B 601 (-3.5A)	0.92A	4v01A-4xeyB: 31.2	4v01A-4xeyB: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 12	ALA B 288 MET B 309 LEU B 373 HIS B 380 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None None 1N1 B 601 (-3.5A)	0.78A	4v01B-4xeyB: 31.4	4v01B-4xeyB: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 11	LEU B 267 ALA B 288 LYS B 290 THR B 334 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.72A	4wa9A-4xeyB: 37.7	4wa9A-4xeyB: 78.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 11	LEU B 267 ALA B 288 THR B 334 MET B 337 GLY B 340 ASN B 387 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.46A	4wa9A-4xeyB: 37.7	4wa9A-4xeyB: 78.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 11	LEU B 267 ALA B 288 THR B 334 MET B 337 GLY B 340 LEU B 389 ALA B 399 PHE B 401	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A) None	0.76A	4wa9A-4xeyB: 37.7	4wa9A-4xeyB: 78.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 THR B 334 PHE B 336 MET B 337 GLY B 340 ASN B 387 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.48A	4wa9B-4xeyB: 40.8	4wa9B-4xeyB: 78.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 THR B 334 PHE B 336 MET B 337 GLY B 340 LEU B 389 ALA B 399 PHE B 401	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A) None	1.09A	4wa9B-4xeyB: 40.8	4wa9B-4xeyB: 78.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_C_ANWC601_0 (RHODOPSIN KINASE)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 6	LEU B 267 ALA B 288 MET B 337 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.60A	4wboC-4xeyB: 22.4	4wboC-4xeyB: 27.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WKQ_A_IREA1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 ALA B 288 LYS B 290 MET B 309 THR B 334 GLY B 340 ASP B 344 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.73A	4wkqA-4xeyB: 33.7	4wkqA-4xeyB: 28.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_A_1N1A601_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 ALA B 288 LYS B 290 MET B 309 VAL B 318 THR B 334 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.55A	4xliA-4xeyB: 32.5	4xliA-4xeyB: 85.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_A_1N1A601_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 ALA B 288 MET B 309 VAL B 318 THR B 334 MET B 337 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.40A	4xliA-4xeyB: 32.5	4xliA-4xeyB: 85.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_B_1N1B600_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	10 / 12	LEU B 267 ALA B 288 LYS B 290 MET B 309 VAL B 318 ILE B 332 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.65A	4xliB-4xeyB: 38.9	4xliB-4xeyB: 85.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAA_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.36A	5aaaA-4xeyB: 31.0	5aaaA-4xeyB: 32.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAB_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 10	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.41A	5aabA-4xeyB: 24.8	5aabA-4xeyB: 32.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 10	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.46A	5aacA-4xeyB: 24.7	5aacA-4xeyB: 31.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 ALA B 288 LYS B 290 PHE B 336 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.76A	5ajqA-4xeyB: 23.3	5ajqA-4xeyB: 24.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 ALA B 288 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.76A	5ajqA-4xeyB: 23.3	5ajqA-4xeyB: 24.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5BVW_A_1N1A1009_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 309 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.78A	5bvwA-4xeyB: 30.4	5bvwA-4xeyB: 29.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5GSN_A_MMZA503_1 (FLAVIN-CONTAINING MONOOXYGENASE)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	3 / 3	ASN B 316 SER B 368 SER B 367	None	0.68A	5gsnA-4xeyB: undetectable	5gsnA-4xeyB: 22.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_A_1N1A501_1 (PROTEIN-TYROSINE KINASE 6)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 THR B 334 GLY B 340	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A)	0.62A	5h2uA-4xeyB: 30.9	5h2uA-4xeyB: 29.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_A_1N1A501_1 (PROTEIN-TYROSINE KINASE 6)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 VAL B 275 ALA B 288 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.46A	5h2uA-4xeyB: 30.9	5h2uA-4xeyB: 29.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 ALA B 288 ILE B 332 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.52A	5h2uC-4xeyB: 30.8	5h2uC-4xeyB: 29.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 ALA B 288 LYS B 290 ILE B 332 THR B 334 GLY B 340	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A)	0.61A	5h2uC-4xeyB: 30.8	5h2uC-4xeyB: 29.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 VAL B 275 ALA B 288 ILE B 332 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.38A	5h2uD-4xeyB: 25.5	5h2uD-4xeyB: 29.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 VAL B 275 ALA B 288 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.44A	5h2uD-4xeyB: 25.5	5h2uD-4xeyB: 29.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HBS_A_RTLA201_0 (RETINOL-BINDING PROTEIN 1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 12	VAL B 190 ALA B 156 SER B 173 ARG B 153 LEU B 214	None	1.20A	5hbsA-4xeyB: undetectable	5hbsA-4xeyB: 16.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_A_032A401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 12	VAL B 275 ALA B 288 ILE B 332 THR B 334 ASP B 344	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) None	0.59A	5hesA-4xeyB: 25.9	5hesA-4xeyB: 26.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	VAL B 275 ALA B 288 LYS B 290 ILE B 332 THR B 334 ASP B 344	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) None	0.65A	5hesB-4xeyB: 25.9	5hesB-4xeyB: 26.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 12	VAL B 275 ALA B 288 LYS B 290 ILE B 332 THR B 334	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A)	0.33A	5hieA-4xeyB: 26.6	5hieA-4xeyB: 25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 12	VAL B 275 ALA B 288 LYS B 290 ILE B 332 THR B 334	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A)	0.34A	5hieB-4xeyB: 26.6	5hieB-4xeyB: 25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 12	VAL B 275 ALA B 288 LYS B 290 ILE B 332 THR B 334	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A)	0.32A	5hieD-4xeyB: 26.6	5hieD-4xeyB: 25.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5I9X_A_DB8A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	ALA B 288 ILE B 332 THR B 334 GLY B 340 GLU B 348 LEU B 389	1N1 B 601 (-3.5A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.52A	5i9xA-4xeyB: 32.2	5i9xA-4xeyB: 31.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5I9Y_A_1N1A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 LYS B 290 MET B 309 THR B 334 GLY B 340 GLU B 348 LEU B 389	1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A)	0.69A	5i9yA-4xeyB: 25.2	5i9yA-4xeyB: 31.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 10	LEU B 267 VAL B 275 ILE B 332 PHE B 336 MET B 337 GLY B 340	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-4.1A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A)	0.78A	5mo4A-4xeyB: 28.4	5mo4A-4xeyB: 80.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 VAL B 308 MET B 309 ILE B 312 LEU B 317 HIS B 380 LEU B 389	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None None None 1N1 B 601 (-4.3A)	0.67A	5mo4A-4xeyB: 28.4	5mo4A-4xeyB: 80.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 VAL B 308 MET B 309 LEU B 317 HIS B 380 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.60A	5mo4A-4xeyB: 28.4	5mo4A-4xeyB: 80.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	ALA B 288 VAL B 308 MET B 309 LEU B 317 VAL B 318 HIS B 380 LEU B 389	1N1 B 601 (-3.5A) None 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) None 1N1 B 601 (-4.3A)	0.65A	5mo4A-4xeyB: 28.4	5mo4A-4xeyB: 80.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	VAL B 275 ALA B 288 LYS B 290 ILE B 332 THR B 334 GLY B 340 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.60A	5p9iA-4xeyB: 25.2	5p9iA-4xeyB: 35.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5TE0_A_XINA401_1 (AP2-ASSOCIATED PROTEIN KINASE 1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	ALA B 288 MET B 309 VAL B 318 PHE B 336 GLY B 340 LEU B 389	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.58A	5te0A-4xeyB: 24.0	5te0A-4xeyB: 24.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 GLY B 340 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.5A)	0.77A	5zv2A-4xeyB: 31.7	5zv2A-4xeyB: 13.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BSD_A_1N1A901_0 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	VAL B 275 ALA B 288 MET B 309 THR B 334 MET B 337 GLY B 340 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.57A	6bsdA-4xeyB: 24.3	6bsdA-4xeyB: 12.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6FNM_A_1N1A1001_1 (-)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 LYS B 290 ILE B 332 THR B 334 MET B 337 GLY B 340 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.43A	6fnmA-4xeyB: 27.1	6fnmA-4xeyB: 32.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HCX_A_ZMRA519_1 (NEURAMINIDASE)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	3 / 3	TRP B 280 ILE B 333 GLU B 255	None	0.81A	6hcxA-4xeyB: undetectable	6hcxA-4xeyB: 10.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD4_A_STIA604_0 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 LYS B 290 MET B 309 ILE B 312 VAL B 318 ILE B 332 THR B 334	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A)	0.67A	6hd4A-4xeyB: 27.9	6hd4A-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD4_A_STIA604_0 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 ILE B 332 THR B 334 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.75A	6hd4A-4xeyB: 27.9	6hd4A-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD4_A_STIA604_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 5	VAL B 308 PHE B 336 MET B 337 GLY B 340	None 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A)	0.35A	6hd4A-4xeyB: 27.9	6hd4A-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD4_B_STIB602_0 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	VAL B 275 ALA B 288 LYS B 290 MET B 309 ILE B 312 VAL B 318 ILE B 332 THR B 334	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A)	0.73A	6hd4B-4xeyB: 34.1	6hd4B-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD4_B_STIB602_0 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 ILE B 332 THR B 334 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.74A	6hd4B-4xeyB: 34.1	6hd4B-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD4_B_STIB602_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	5 / 6	LEU B 267 VAL B 308 PHE B 336 MET B 337 GLY B 340	1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A)	0.74A	6hd4B-4xeyB: 34.1	6hd4B-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD6_A_STIA603_0 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	7 / 12	VAL B 275 ALA B 288 LYS B 290 MET B 309 VAL B 318 ILE B 332 THR B 334	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A)	0.62A	6hd6A-4xeyB: 34.3	6hd6A-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD6_A_STIA603_0 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	VAL B 275 ALA B 288 MET B 309 VAL B 318 ILE B 332 THR B 334 PHE B 336 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-4.1A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.63A	6hd6A-4xeyB: 34.3	6hd6A-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD6_A_STIA603_1 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	4 / 5	LEU B 267 ILE B 312 MET B 337 GLY B 340	1N1 B 601 (-3.7A) None None 1N1 B 601 (-3.5A)	0.98A	6hd6A-4xeyB: 34.3	6hd6A-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD6_B_STIB601_0 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 12	LEU B 267 VAL B 275 ALA B 288 LYS B 290 MET B 309 ILE B 312 VAL B 318 THR B 334	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A)	0.83A	6hd6B-4xeyB: 34.1	6hd6B-4xeyB: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6HD6_B_STIB601_0 (TYROSINE-PROTEIN KINASE ABL1)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 12	LEU B 267 VAL B 275 ALA B 288 MET B 309 ILE B 312 VAL B 318 THR B 334 PHE B 336 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-4.3A)	0.83A	6hd6B-4xeyB: 34.1	6hd6B-4xeyB: 40.64

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1FDU_D_ESTD352_1","17-BETA-HYDROXYSTEROID DEHYDROGENASE","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 323;GLY B 322;LEU B 320;GLU B 311","None","1.03A","1fduD-4xeyB:undetectable","1fduD-4xeyB:20.37"],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;MET B 309;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.81A","1iepA-4xeyB:35.1","1iepA-4xeyB:71.50"],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;MET B 309;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.67A","1iepA-4xeyB:35.1","1iepA-4xeyB:71.50"],["1IEP_A_STIA201_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LYS B 290;VAL B 308;VAL B 318;ILE B 332","1N1 B 601 (-4.6A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.85A","1iepA-4xeyB:35.1","1iepA-4xeyB:71.50"],["1IEP_A_STIA201_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 308;VAL B 318;ILE B 332;MET B 337","None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None","0.55A","1iepA-4xeyB:35.1","1iepA-4xeyB:71.50"],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-3.5A)","0.95A","1iepB-4xeyB:29.0","1iepB-4xeyB:71.50"],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-3.5A)","0.85A","1iepB-4xeyB:29.0","1iepB-4xeyB:71.50"],["1IEP_B_STIB202_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LYS B 290;VAL B 308;VAL B 318;ILE B 332","1N1 B 601 (-4.6A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.53A","1iepB-4xeyB:29.0","1iepB-4xeyB:71.50"],["1IEP_B_STIB202_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 308;ILE B 332;MET B 337;LEU B 389","None;1N1 B 601 (-4.1A);None;1N1 B 601 (-4.3A)","0.62A","1iepB-4xeyB:29.0","1iepB-4xeyB:71.50"],["1IEP_B_STIB202_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 308;VAL B 318;ILE B 332;LEU B 389","None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-4.3A)","0.66A","1iepB-4xeyB:29.0","1iepB-4xeyB:71.50"],["1JLF_A_NVPA999_1","HIV-1 RT A-CHAIN;HIV-1 RT B-CHAIN","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 346;VAL B 390;CYH B 388;GLY B 340","None;None;None;1N1 B 601 (-3.5A)","1.02A","1jlfA-4xeyB:undetectable;1jlfB-4xeyB:undetectable","1jlfA-4xeyB:20.51;1jlfB-4xeyB:22.83"],["1M17_A_AQ4A999_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;ALA B 288;LYS B 290;THR B 334;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.42A","1m17A-4xeyB:28.0","1m17A-4xeyB:28.47"],["1OPJ_A_STIA3_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;VAL B 275;ILE B 312;VAL B 318;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);None;1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.88A","1opjA-4xeyB:34.0","1opjA-4xeyB:71.50"],["1OPJ_A_STIA3_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.80A","1opjA-4xeyB:34.0","1opjA-4xeyB:71.50"],["1OPJ_A_STIA3_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.64A","1opjA-4xeyB:34.0","1opjA-4xeyB:71.50"],["1OPJ_B_STIB4_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;THR B 334;PHE B 336;GLY B 340;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-3.5A)","0.87A","1opjB-4xeyB:27.9","1opjB-4xeyB:71.50"],["1OPJ_B_STIB4_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;LYS B 290;VAL B 308;ILE B 332","1N1 B 601 (-3.7A);1N1 B 601 (-4.6A);None;1N1 B 601 (-4.1A)","0.91A","1opjB-4xeyB:27.9","1opjB-4xeyB:71.50"],["1OPJ_B_STIB4_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;VAL B 308;ILE B 332;MET B 337","1N1 B 601 (-3.7A);None;1N1 B 601 (-4.1A);None","0.64A","1opjB-4xeyB:27.9","1opjB-4xeyB:71.50"],["1T46_A_STIA3_1","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;VAL B 318;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.78A","1t46A-4xeyB:26.6","1t46A-4xeyB:29.76"],["1XBB_A_STIA1_1","TYROSINE-PROTEIN KINASE SYK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"LEU B 267;VAL B 275;ALA B 288;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.31A","1xbbA-4xeyB:29.5","1xbbA-4xeyB:33.65"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"ALA B 288;THR B 334;GLY B 340;LEU B 343;ASP B 344;LEU B 389","1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;None;1N1 B 601 (-4.3A)","0.87A","1xkkA-4xeyB:26.3","1xkkA-4xeyB:29.61"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"THR B 334;GLY B 340;LEU B 343;ASP B 344;ARG B 347;LEU B 389","1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;None;None;1N1 B 601 (-4.3A)","0.68A","1xkkA-4xeyB:26.3","1xkkA-4xeyB:29.61"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"ALA B 288;LYS B 290;MET B 309;VAL B 318;ILE B 332;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.65A","2gqgA-4xeyB:32.2","2gqgA-4xeyB:71.17"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"LEU B 267;ALA B 288;MET B 309;VAL B 318;ILE B 332;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.52A","2gqgA-4xeyB:32.2","2gqgA-4xeyB:71.17"],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;ILE B 332;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.40A","2gqgB-4xeyB:38.3","2gqgB-4xeyB:71.17"],["2HDN_L_TACL6888_1","ELONGATION FACTOR EF-TU;ELONGATION FACTOR EF-TU;ELONGATION FACTOR EF-TU","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"SER B 439;VAL B 441;SER B 436;ASP B 410","None","1.16A","2hdnJ-4xeyB:undetectable;2hdnK-4xeyB:undetectable;2hdnL-4xeyB:undetectable","2hdnJ-4xeyB:22.40;2hdnK-4xeyB:8.82;2hdnL-4xeyB:22.40"],["2HYY_A_STIA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.89A","2hyyA-4xeyB:35.3","2hyyA-4xeyB:100.00"],["2HYY_B_STIB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.78A","2hyyB-4xeyB:35.8","2hyyB-4xeyB:100.00"],["2HYY_B_STIB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;LYS B 290;VAL B 318;ILE B 332","1N1 B 601 (-3.7A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.91A","2hyyB-4xeyB:35.8","2hyyB-4xeyB:100.00"],["2HYY_B_STIB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;VAL B 308;ILE B 332;MET B 337","1N1 B 601 (-3.7A);None;1N1 B 601 (-4.1A);None","0.68A","2hyyB-4xeyB:35.8","2hyyB-4xeyB:100.00"],["2HYY_B_STIB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;VAL B 308;VAL B 318;ILE B 332","1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.59A","2hyyB-4xeyB:35.8","2hyyB-4xeyB:100.00"],["2HYY_C_STIC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;ILE B 312;VAL B 318;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.69A","2hyyC-4xeyB:36.1","2hyyC-4xeyB:100.00"],["2HYY_C_STIC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"LEU B 267;LYS B 290;VAL B 308;MET B 309;ILE B 332","1N1 B 601 (-3.7A);1N1 B 601 (-4.6A);None;1N1 B 601 (-3.7A);1N1 B 601 (-4.1A)","0.88A","2hyyC-4xeyB:36.1","2hyyC-4xeyB:100.00"],["2HYY_C_STIC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"LEU B 267;VAL B 308;MET B 309;ILE B 332;MET B 337","1N1 B 601 (-3.7A);None;1N1 B 601 (-3.7A);1N1 B 601 (-4.1A);None","0.61A","2hyyC-4xeyB:36.1","2hyyC-4xeyB:100.00"],["2HYY_D_STID600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;MET B 309;ILE B 312;ILE B 332;THR B 334;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.83A","2hyyD-4xeyB:35.4","2hyyD-4xeyB:100.00"],["2ITO_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;ALA B 288;LYS B 290;MET B 309;THR B 334;GLY B 340","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A)","0.67A","2itoA-4xeyB:26.8","2itoA-4xeyB:28.51"],["2ITO_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;ALA B 288;LYS B 290;THR B 334;GLY B 340;ASP B 344;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.63A","2itoA-4xeyB:26.8","2itoA-4xeyB:28.51"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 309;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.69A","2ityA-4xeyB:26.7","2ityA-4xeyB:28.25"],["2ITZ_A_IREA2021_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 309;THR B 334;GLY B 340","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A)","0.61A","2itzA-4xeyB:26.3","2itzA-4xeyB:28.02"],["2ITZ_A_IREA2021_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;THR B 334;GLY B 340;ASP B 344;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.68A","2itzA-4xeyB:26.3","2itzA-4xeyB:28.02"],["2OIQ_A_STIA1001_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;MET B 309;ILE B 332;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.59A","2oiqA-4xeyB:32.6","2oiqA-4xeyB:36.32"],["2PL0_A_STIA200_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;MET B 309;VAL B 318;ILE B 332;THR B 334;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.83A","2pl0A-4xeyB:26.1","2pl0A-4xeyB:37.17"],["2PL0_A_STIA200_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"VAL B 275;ALA B 288;LYS B 290;MET B 309;VAL B 318;ILE B 332;THR B 334","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A)","0.76A","2pl0A-4xeyB:26.1","2pl0A-4xeyB:37.17"],["2PL0_A_STIA200_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"VAL B 275;ALA B 288;MET B 309;VAL B 318;ILE B 332;THR B 334;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A)","0.83A","2pl0A-4xeyB:26.1","2pl0A-4xeyB:37.17"],["2XP2_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.41A","2xp2A-4xeyB:13.4","2xp2A-4xeyB:31.91"],["2Y6O_A_1N1A1892_1","EPHRIN TYPE-A RECEPTOR 4","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;LYS B 290;MET B 309;ILE B 332;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.61A","2y6oA-4xeyB:28.0","2y6oA-4xeyB:31.89"],["2Y7J_C_B49C1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"VAL B 275;ALA B 288;MET B 337;GLY B 340;ASP B 344;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.52A","2y7jC-4xeyB:19.8","2y7jC-4xeyB:26.06"],["2Y7J_D_B49D1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"VAL B 275;ALA B 288;MET B 337;GLY B 340;ASP B 344;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.66A","2y7jD-4xeyB:25.8","2y7jD-4xeyB:26.06"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",11,"LEU B 267;ALA B 288;LYS B 290;MET B 309;VAL B 318;ILE B 332;THR B 334;MET B 337;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.58A","2zvaA-4xeyB:33.3","2zvaA-4xeyB:34.96"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;ALA B 288;LYS B 290;VAL B 318;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.59A","3aoxA-4xeyB:25.2","3aoxA-4xeyB:32.62"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"VAL B 275;ALA B 288;LEU B 320;THR B 334;GLY B 340;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.63A","3bbtB-4xeyB:25.0","3bbtB-4xeyB:29.77"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;GLU B 277;ALA B 288;LYS B 290;VAL B 318;PHE B 336;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.83A","3c7qA-4xeyB:30.8","3c7qA-4xeyB:32.10"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;LYS B 290;LYS B 304;ILE B 332;VAL B 398","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-4.6A);None;1N1 B 601 (-4.1A);None","1.16A","3cs9A-4xeyB:35.8","3cs9A-4xeyB:74.39"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;LYS B 290;VAL B 318;ILE B 332;VAL B 398","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None","0.83A","3cs9A-4xeyB:35.8","3cs9A-4xeyB:74.39"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;LYS B 304;ILE B 332;PHE B 336;VAL B 398","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);None;1N1 B 601 (-4.1A);1N1 B 601 ( 4.2A);None","0.98A","3cs9A-4xeyB:35.8","3cs9A-4xeyB:74.39"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;VAL B 318;ILE B 332;PHE B 336;VAL B 398","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 ( 4.2A);None","0.68A","3cs9A-4xeyB:35.8","3cs9A-4xeyB:74.39"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"ALA B 288;VAL B 308;MET B 309;LEU B 317;THR B 334;GLY B 340;HIS B 380;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.52A","3cs9A-4xeyB:35.8","3cs9A-4xeyB:74.39"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 308;MET B 309;ILE B 312;LEU B 317;GLY B 340;HIS B 380;LEU B 389;ALA B 399","None;1N1 B 601 (-3.7A);None;None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.66A","3cs9A-4xeyB:35.8","3cs9A-4xeyB:74.39"],["3CS9_B_NILB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"ALA B 288;VAL B 308;MET B 309;ILE B 312;LEU B 317;GLY B 340;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;None;1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A)","0.68A","3cs9B-4xeyB:30.5","3cs9B-4xeyB:74.39"],["3CS9_B_NILB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"ALA B 288;VAL B 308;MET B 309;LEU B 317;THR B 334;GLY B 340;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A)","0.49A","3cs9B-4xeyB:30.5","3cs9B-4xeyB:74.39"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;VAL B 275;LYS B 290;VAL B 318;ILE B 332;PHE B 378;VAL B 398","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None;None","0.81A","3cs9B-4xeyB:30.5","3cs9B-4xeyB:74.39"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;VAL B 275;VAL B 318;ILE B 332;PHE B 378;LEU B 389;VAL B 398","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None;1N1 B 601 (-4.3A);None","0.67A","3cs9B-4xeyB:30.5","3cs9B-4xeyB:74.39"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"ALA B 288;VAL B 308;MET B 309;ILE B 312;LEU B 317;THR B 334;PHE B 336;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A)","0.72A","3cs9C-4xeyB:29.2","3cs9C-4xeyB:74.39"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"VAL B 308;MET B 309;ILE B 312;LEU B 317;THR B 334;PHE B 378","None;1N1 B 601 (-3.7A);None;None;1N1 B 601 (-3.3A);None","1.48A","3cs9C-4xeyB:29.2","3cs9C-4xeyB:74.39"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;LYS B 290;VAL B 318;ILE B 332;VAL B 398","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None","0.83A","3cs9C-4xeyB:29.2","3cs9C-4xeyB:74.39"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;VAL B 318;ILE B 332;MET B 337;VAL B 398","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None;None","0.67A","3cs9C-4xeyB:29.2","3cs9C-4xeyB:74.39"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"ALA B 288;VAL B 308;MET B 309;ILE B 312;LEU B 317;PHE B 336;GLY B 340;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;None;1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A)","0.68A","3cs9D-4xeyB:33.6","3cs9D-4xeyB:74.39"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"ALA B 288;VAL B 308;MET B 309;LEU B 317;THR B 334;PHE B 336;GLY B 340;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A)","0.52A","3cs9D-4xeyB:33.6","3cs9D-4xeyB:74.39"],["3G0F_B_B49B9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.71A","3g0fB-4xeyB:30.6","3g0fB-4xeyB:30.19"],["3G5D_A_1N1A1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;ILE B 332;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.41A","3g5dA-4xeyB:27.3","3g5dA-4xeyB:36.32"],["3G5D_B_1N1B1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.51A","3g5dB-4xeyB:27.4","3g5dB-4xeyB:36.32"],["3GVU_A_STIA1001_1","TYROSINE-PROTEIN KINASE ABL2","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;THR B 334;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.78A","3gvuA-4xeyB:29.1","3gvuA-4xeyB:64.46"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;MET B 309;ILE B 312;LEU B 317;HIS B 380;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;None;None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.63A","3ik3A-4xeyB:36.3","3ik3A-4xeyB:92.21"],["3IK3_A_0LIA1_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;VAL B 308;ILE B 332;MET B 337","1N1 B 601 (-3.7A);None;1N1 B 601 (-4.1A);None","0.60A","3ik3A-4xeyB:36.3","3ik3A-4xeyB:92.21"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;MET B 309;ILE B 312;LEU B 317;HIS B 380;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;None;None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.59A","3ik3B-4xeyB:30.1","3ik3B-4xeyB:92.21"],["3IK3_B_0LIB2_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;VAL B 308;ILE B 332;MET B 337","1N1 B 601 (-3.7A);None;1N1 B 601 (-4.1A);None","0.63A","3ik3B-4xeyB:30.1","3ik3B-4xeyB:92.21"],["3K54_A_1N1A1_1","TYROSINE-PROTEIN KINASE BTK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;ALA B 288;LYS B 290;MET B 309;VAL B 318;ILE B 332;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.55A","3k54A-4xeyB:26.7","3k54A-4xeyB:36.25"],["3K5V_A_STIA2_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.79A","3k5vA-4xeyB:34.2","3k5vA-4xeyB:71.50"],["3K5V_A_STIA2_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;LYS B 290;VAL B 318;ILE B 332","1N1 B 601 (-3.7A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.82A","3k5vA-4xeyB:34.2","3k5vA-4xeyB:71.50"],["3K5V_B_STIB2_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.77A","3k5vB-4xeyB:34.2","3k5vB-4xeyB:71.50"],["3K5V_B_STIB2_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;LYS B 290;VAL B 318;ILE B 332","1N1 B 601 (-3.7A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.91A","3k5vB-4xeyB:34.2","3k5vB-4xeyB:71.50"],["3MIY_A_B49A1_1","TYROSINE-PROTEIN KINASE ITK\/TSK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;LYS B 290;VAL B 318;PHE B 336;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.79A","3miyA-4xeyB:26.2","3miyA-4xeyB:30.47"],["3MIY_B_B49B2_1","TYROSINE-PROTEIN KINASE ITK\/TSK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"ALA B 288;LYS B 290;PHE B 336;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.59A","3miyB-4xeyB:27.2","3miyB-4xeyB:30.47"],["3MS9_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.86A","3ms9A-4xeyB:35.1","3ms9A-4xeyB:71.50"],["3MS9_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LYS B 290;VAL B 308;VAL B 318;ILE B 332","1N1 B 601 (-4.6A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.73A","3ms9A-4xeyB:35.1","3ms9A-4xeyB:71.50"],["3MS9_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 308;VAL B 318;ILE B 332;MET B 337","None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None","0.51A","3ms9A-4xeyB:35.1","3ms9A-4xeyB:71.50"],["3MS9_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"LEU B 267;VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.86A","3ms9B-4xeyB:35.4","3ms9B-4xeyB:71.50"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.86A","3mssA-4xeyB:35.4","3mssA-4xeyB:71.50"],["3MSS_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LYS B 290;VAL B 308;VAL B 318;ILE B 332","1N1 B 601 (-4.6A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.74A","3mssA-4xeyB:35.4","3mssA-4xeyB:71.50"],["3MSS_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 308;VAL B 318;ILE B 332;MET B 337","None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None","0.54A","3mssA-4xeyB:35.4","3mssA-4xeyB:71.50"],["3MSS_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;MET B 309;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.46A","3mssB-4xeyB:29.7","3mssB-4xeyB:71.50"],["3MSS_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"VAL B 275;ALA B 288;MET B 309;THR B 334;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.66A","3mssB-4xeyB:29.7","3mssB-4xeyB:71.50"],["3MSS_B_STIB1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LYS B 290;VAL B 308;VAL B 318;ILE B 332","1N1 B 601 (-4.6A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.82A","3mssB-4xeyB:29.7","3mssB-4xeyB:71.50"],["3MSS_B_STIB1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 308;VAL B 318;ILE B 332;MET B 337","None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None","0.55A","3mssB-4xeyB:29.7","3mssB-4xeyB:71.50"],["3MSS_C_STIC1_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.87A","3mssC-4xeyB:35.3","3mssC-4xeyB:71.50"],["3MSS_C_STIC1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LYS B 290;VAL B 308;VAL B 318;ILE B 332","1N1 B 601 (-4.6A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.74A","3mssC-4xeyB:35.3","3mssC-4xeyB:71.50"],["3MSS_C_STIC1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 308;VAL B 318;ILE B 332;MET B 337","None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None","0.57A","3mssC-4xeyB:35.3","3mssC-4xeyB:71.50"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.74A","3mssD-4xeyB:35.4","3mssD-4xeyB:71.50"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.91A","3mssD-4xeyB:35.4","3mssD-4xeyB:71.50"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"VAL B 275;LYS B 290;VAL B 308;VAL B 318;ILE B 332","1N1 B 601 ( 4.9A);1N1 B 601 (-4.6A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.75A","3mssD-4xeyB:35.4","3mssD-4xeyB:71.50"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"VAL B 275;VAL B 308;VAL B 318;ILE B 332;MET B 337","1N1 B 601 ( 4.9A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);None","0.60A","3mssD-4xeyB:35.4","3mssD-4xeyB:71.50"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.51A","3octA-4xeyB:13.6","3octA-4xeyB:33.76"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;GLY B 340;GLU B 348;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","1.11A","3octA-4xeyB:13.6","3octA-4xeyB:33.76"],["3OEZ_A_STIA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.59A","3oezA-4xeyB:24.4","3oezA-4xeyB:36.57"],["3OEZ_A_STIA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;THR B 334;GLY B 340;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.59A","3oezA-4xeyB:24.4","3oezA-4xeyB:36.57"],["3OEZ_B_STIB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;LYS B 290;VAL B 308;MET B 309;ILE B 332;THR B 334;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);None;1N1 B 601 (-3.7A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.53A","3oezB-4xeyB:25.1","3oezB-4xeyB:36.57"],["3OKX_A_SAMA201_0","YAEB-LIKE PROTEIN RPA0152","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"LEU B 160;HIS B 233;LEU B 184;SER B 222;LEU B 169","None","1.31A","3okxA-4xeyB:undetectable","3okxA-4xeyB:17.28"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"ALA B 288;MET B 309;ILE B 312;LEU B 317;VAL B 318;THR B 334;GLY B 340;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;None;1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A)","0.56A","3oxzA-4xeyB:30.8","3oxzA-4xeyB:93.09"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"LEU B 267;LYS B 290;VAL B 308;ILE B 332;VAL B 398","1N1 B 601 (-3.7A);1N1 B 601 (-4.6A);None;1N1 B 601 (-4.1A);None","0.84A","3oxzA-4xeyB:30.8","3oxzA-4xeyB:93.09"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 308;ILE B 332;MET B 337;LEU B 389;VAL B 398","1N1 B 601 (-3.7A);None;1N1 B 601 (-4.1A);None;1N1 B 601 (-4.3A);None","0.50A","3oxzA-4xeyB:30.8","3oxzA-4xeyB:93.09"],["3PYY_A_STIA3_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.57A","3pyyA-4xeyB:29.9","3pyyA-4xeyB:73.05"],["3PYY_A_STIA3_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"VAL B 275;ALA B 288;MET B 309;ILE B 312;THR B 334;PHE B 336;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A)","0.70A","3pyyA-4xeyB:29.9","3pyyA-4xeyB:73.05"],["3PYY_A_STIA3_2","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LYS B 290;VAL B 308;VAL B 318;ILE B 332","1N1 B 601 (-4.6A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A)","0.97A","3pyyA-4xeyB:29.9","3pyyA-4xeyB:73.05"],["3PYY_B_STIB4_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.72A","3pyyB-4xeyB:31.0","3pyyB-4xeyB:73.05"],["3PYY_B_STIB4_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;THR B 334;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.66A","3pyyB-4xeyB:31.0","3pyyB-4xeyB:73.05"],["3QLG_A_1N1A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.45A","3qlgA-4xeyB:32.4","3qlgA-4xeyB:36.57"],["3QLG_A_1N1A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;LYS B 290;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.60A","3qlgA-4xeyB:32.4","3qlgA-4xeyB:36.57"],["3QLG_B_1N1B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.44A","3qlgB-4xeyB:27.3","3qlgB-4xeyB:36.57"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.57A","3sxrA-4xeyB:33.4","3sxrA-4xeyB:30.88"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;VAL B 318;ILE B 332;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.44A","3sxrA-4xeyB:33.4","3sxrA-4xeyB:30.88"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.53A","3sxrB-4xeyB:33.7","3sxrB-4xeyB:30.88"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;VAL B 318;THR B 334;GLY B 340;LEU B 389;PHE B 401","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);None","0.86A","3sxrB-4xeyB:33.7","3sxrB-4xeyB:30.88"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"LEU B 267;ALA B 288;LYS B 290;VAL B 318;ILE B 332;THR B 334;PHE B 336;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.38A","3ue4A-4xeyB:34.3","3ue4A-4xeyB:93.77"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"LEU B 267;VAL B 275;ALA B 288;MET B 309;VAL B 318;ILE B 332;THR B 334;PHE B 336;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.33A","3ue4B-4xeyB:40.5","3ue4B-4xeyB:93.77"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 337;GLY B 340;ASP B 344;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.61A","3ug2A-4xeyB:28.5","3ug2A-4xeyB:28.74"],["3ZBF_A_VGHA3000_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"LEU B 267;ALA B 288;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.30A","3zbfA-4xeyB:32.7","3zbfA-4xeyB:33.58"],["3ZOS_A_0LIA1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;ALA B 288;LYS B 290;THR B 334;HIS B 380;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.3A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.81A","3zosA-4xeyB:29.8","3zosA-4xeyB:29.67"],["4AG8_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;VAL B 318;PHE B 336;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.74A","4ag8A-4xeyB:26.2","4ag8A-4xeyB:29.68"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;ALA B 288;LYS B 290;PHE B 336;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.68A","4agdA-4xeyB:30.9","4agdA-4xeyB:32.42"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;ALA B 288;VAL B 318;PHE B 336;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.56A","4agdA-4xeyB:30.9","4agdA-4xeyB:32.42"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.67A","4anqA-4xeyB:25.6","4anqA-4xeyB:32.86"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.36A","4anqA-4xeyB:25.6","4anqA-4xeyB:32.86"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.65A","4ansA-4xeyB:25.5","4ansA-4xeyB:32.86"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.34A","4ansA-4xeyB:25.5","4ansA-4xeyB:32.86"],["4BKJ_B_STIB1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"VAL B 275;ALA B 288;MET B 309;THR B 334;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.88A","4bkjB-4xeyB:30.1","4bkjB-4xeyB:29.67"],["4C8B_A_0LIA1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;LYS B 290;ILE B 332;THR B 334;HIS B 380;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.64A","4c8bA-4xeyB:26.1","4c8bA-4xeyB:24.94"],["4CSV_A_STIA1265_1","SRC-ABL TYROSINE KINASE ANCESTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"VAL B 275;ALA B 288;MET B 309;THR B 334;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.56A","4csvA-4xeyB:27.2","4csvA-4xeyB:48.31"],["4DF2_A_4CHA506_0","NADPH DEHYDROGENASE","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"THR B 291;TYR B 276;HIS B 233;TYR B 331","None","1.16A","4df2A-4xeyB:undetectable","4df2A-4xeyB:24.89"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;THR B 334;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.42A","4hjoA-4xeyB:30.3","4hjoA-4xeyB:28.93"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 309;VAL B 318;ILE B 332;THR B 334;GLY B 340","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A)","0.66A","4mxoA-4xeyB:33.6","4mxoA-4xeyB:36.32"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;VAL B 318;ILE B 332;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.47A","4mxoB-4xeyB:33.1","4mxoB-4xeyB:36.32"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;ALA B 288;LYS B 290;MET B 309;VAL B 318;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.73A","4mxxA-4xeyB:33.2","4mxxA-4xeyB:36.07"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;ALA B 288;LYS B 290;VAL B 318;ILE B 332;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.49A","4mxxA-4xeyB:33.2","4mxxA-4xeyB:36.07"],["4MXX_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;VAL B 318;THR B 334;MET B 337;GLY B 340;LEU B 389;PHE B 401","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);None","0.57A","4mxxB-4xeyB:32.5","4mxxB-4xeyB:36.07"],["4MXY_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;VAL B 275;ALA B 288;VAL B 318;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.51A","4mxyB-4xeyB:26.8","4mxyB-4xeyB:35.82"],["4MXZ_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;VAL B 275;ALA B 288;VAL B 318;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.51A","4mxzB-4xeyB:26.8","4mxzB-4xeyB:35.82"],["4O0U_A_ADNA501_1","AURORA KINASE A","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 275;ALA B 288;LYS B 290;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-4.3A)","0.52A","4o0uA-4xeyB:8.2","4o0uA-4xeyB:23.47"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;LYS B 290;VAL B 318;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.55A","4otwA-4xeyB:25.7","4otwA-4xeyB:27.65"],["4R29_D_SAMD301_1","UNCHARACTERIZED PROTEIN","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",3,"ARG B 381;GLU B 300;TYR B 412","None","0.99A","4r29D-4xeyB:undetectable","4r29D-4xeyB:19.70"],["4R7I_A_STIA1001_1","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"VAL B 275;ALA B 288;LYS B 290;MET B 309;THR B 334;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A)","0.55A","4r7iA-4xeyB:31.4","4r7iA-4xeyB:31.08"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;LYS B 290;PHE B 336;MET B 337;ASN B 387;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.2A);None;None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.73A","4twpA-4xeyB:34.2","4twpA-4xeyB:99.63"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;PHE B 336;MET B 337;GLY B 340;ASN B 387;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.58A","4twpA-4xeyB:34.2","4twpA-4xeyB:99.63"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;LYS B 290;PHE B 336;MET B 337;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.77A","4twpB-4xeyB:33.1","4twpB-4xeyB:99.63"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;PHE B 336;MET B 337;GLY B 340;ASN B 387;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.62A","4twpB-4xeyB:33.1","4twpB-4xeyB:99.63"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;LYS B 290;PHE B 336;MET B 337;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.76A","4twpB-4xeyB:33.1","4twpB-4xeyB:99.63"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;PHE B 336;MET B 337;GLY B 340;ASN B 387;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.58A","4twpB-4xeyB:33.1","4twpB-4xeyB:99.63"],["4TYJ_A_0LIA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"ALA B 288;MET B 309;ILE B 312;HIS B 380;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.61A","4tyjA-4xeyB:32.4","4tyjA-4xeyB:32.47"],["4U5J_A_RXTA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;MET B 337;GLY B 340;ASN B 387;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.53A","4u5jA-4xeyB:34.3","4u5jA-4xeyB:36.32"],["4U5J_B_RXTB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.27A","4u5jB-4xeyB:28.1","4u5jB-4xeyB:36.32"],["4UCI_A_ADNA2414_1","RNA-DIRECTED RNA POLYMERASE L","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"GLU B 371;PHE B 505;PHE B 444;HIS B 509","None","1.25A","4uciA-4xeyB:undetectable","4uciA-4xeyB:23.35"],["4V01_A_0LIA1776_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"ALA B 288;MET B 309;ILE B 312;LEU B 373;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;None;None;1N1 B 601 (-3.5A)","0.92A","4v01A-4xeyB:31.2","4v01A-4xeyB:31.60"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"ALA B 288;MET B 309;LEU B 373;HIS B 380;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;None;1N1 B 601 (-3.5A)","0.78A","4v01B-4xeyB:31.4","4v01B-4xeyB:31.60"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;ALA B 288;LYS B 290;THR B 334;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.72A","4wa9A-4xeyB:37.7","4wa9A-4xeyB:78.14"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;ALA B 288;THR B 334;MET B 337;GLY B 340;ASN B 387;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.46A","4wa9A-4xeyB:37.7","4wa9A-4xeyB:78.14"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;ALA B 288;THR B 334;MET B 337;GLY B 340;LEU B 389;ALA B 399;PHE B 401","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A);None","0.76A","4wa9A-4xeyB:37.7","4wa9A-4xeyB:78.14"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;THR B 334;PHE B 336;MET B 337;GLY B 340;ASN B 387;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.48A","4wa9B-4xeyB:40.8","4wa9B-4xeyB:78.14"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;THR B 334;PHE B 336;MET B 337;GLY B 340;LEU B 389;ALA B 399;PHE B 401","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A);None","1.09A","4wa9B-4xeyB:40.8","4wa9B-4xeyB:78.14"],["4WBO_C_ANWC601_0","RHODOPSIN KINASE","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;ALA B 288;MET B 337;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.60A","4wboC-4xeyB:22.4","4wboC-4xeyB:27.39"],["4WKQ_A_IREA1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;ALA B 288;LYS B 290;MET B 309;THR B 334;GLY B 340;ASP B 344;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.73A","4wkqA-4xeyB:33.7","4wkqA-4xeyB:28.47"],["4XLI_A_1N1A601_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;ALA B 288;LYS B 290;MET B 309;VAL B 318;THR B 334;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.55A","4xliA-4xeyB:32.5","4xliA-4xeyB:85.22"],["4XLI_A_1N1A601_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;ALA B 288;MET B 309;VAL B 318;THR B 334;MET B 337;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.40A","4xliA-4xeyB:32.5","4xliA-4xeyB:85.22"],["4XLI_B_1N1B600_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",10,"LEU B 267;ALA B 288;LYS B 290;MET B 309;VAL B 318;ILE B 332;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.65A","4xliB-4xeyB:38.9","4xliB-4xeyB:85.22"],["5AAA_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.36A","5aaaA-4xeyB:31.0","5aaaA-4xeyB:32.15"],["5AAB_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.41A","5aabA-4xeyB:24.8","5aabA-4xeyB:32.15"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.46A","5aacA-4xeyB:24.7","5aacA-4xeyB:31.91"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;ALA B 288;LYS B 290;PHE B 336;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.76A","5ajqA-4xeyB:23.3","5ajqA-4xeyB:24.65"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;ALA B 288;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.76A","5ajqA-4xeyB:23.3","5ajqA-4xeyB:24.65"],["5BVW_A_1N1A1009_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 309;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.78A","5bvwA-4xeyB:30.4","5bvwA-4xeyB:29.73"],["5GSN_A_MMZA503_1","FLAVIN-CONTAINING MONOOXYGENASE","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",3,"ASN B 316;SER B 368;SER B 367","None","0.68A","5gsnA-4xeyB:undetectable","5gsnA-4xeyB:22.18"],["5H2U_A_1N1A501_1","PROTEIN-TYROSINE KINASE 6","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;THR B 334;GLY B 340","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A)","0.62A","5h2uA-4xeyB:30.9","5h2uA-4xeyB:29.44"],["5H2U_A_1N1A501_1","PROTEIN-TYROSINE KINASE 6","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.46A","5h2uA-4xeyB:30.9","5h2uA-4xeyB:29.44"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;ALA B 288;ILE B 332;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.52A","5h2uC-4xeyB:30.8","5h2uC-4xeyB:29.44"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;ALA B 288;LYS B 290;ILE B 332;THR B 334;GLY B 340","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A)","0.61A","5h2uC-4xeyB:30.8","5h2uC-4xeyB:29.44"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;ILE B 332;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.1A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.38A","5h2uD-4xeyB:25.5","5h2uD-4xeyB:29.44"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.44A","5h2uD-4xeyB:25.5","5h2uD-4xeyB:29.44"],["5HBS_A_RTLA201_0","RETINOL-BINDING PROTEIN 1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"VAL B 190;ALA B 156;SER B 173;ARG B 153;LEU B 214","None","1.20A","5hbsA-4xeyB:undetectable","5hbsA-4xeyB:16.42"],["5HES_A_032A401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"VAL B 275;ALA B 288;ILE B 332;THR B 334;ASP B 344","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);None","0.59A","5hesA-4xeyB:25.9","5hesA-4xeyB:26.18"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"VAL B 275;ALA B 288;LYS B 290;ILE B 332;THR B 334;ASP B 344","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);None","0.65A","5hesB-4xeyB:25.9","5hesB-4xeyB:26.18"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"VAL B 275;ALA B 288;LYS B 290;ILE B 332;THR B 334","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A)","0.33A","5hieA-4xeyB:26.6","5hieA-4xeyB:25.78"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"VAL B 275;ALA B 288;LYS B 290;ILE B 332;THR B 334","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A)","0.34A","5hieB-4xeyB:26.6","5hieB-4xeyB:25.78"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"VAL B 275;ALA B 288;LYS B 290;ILE B 332;THR B 334","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A)","0.32A","5hieD-4xeyB:26.6","5hieD-4xeyB:25.78"],["5I9X_A_DB8A1001_1","EPHRIN TYPE-A RECEPTOR 2","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"ALA B 288;ILE B 332;THR B 334;GLY B 340;GLU B 348;LEU B 389","1N1 B 601 (-3.5A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.52A","5i9xA-4xeyB:32.2","5i9xA-4xeyB:31.06"],["5I9Y_A_1N1A1001_1","EPHRIN TYPE-A RECEPTOR 2","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;LYS B 290;MET B 309;THR B 334;GLY B 340;GLU B 348;LEU B 389","1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A)","0.69A","5i9yA-4xeyB:25.2","5i9yA-4xeyB:31.06"],["5MO4_A_NILA601_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ILE B 332;PHE B 336;MET B 337;GLY B 340","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-4.1A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A)","0.78A","5mo4A-4xeyB:28.4","5mo4A-4xeyB:80.73"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;VAL B 308;MET B 309;ILE B 312;LEU B 317;HIS B 380;LEU B 389","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;None;None;1N1 B 601 (-4.3A)","0.67A","5mo4A-4xeyB:28.4","5mo4A-4xeyB:80.73"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;VAL B 308;MET B 309;LEU B 317;HIS B 380;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.60A","5mo4A-4xeyB:28.4","5mo4A-4xeyB:80.73"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"ALA B 288;VAL B 308;MET B 309;LEU B 317;VAL B 318;HIS B 380;LEU B 389","1N1 B 601 (-3.5A);None;1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);None;1N1 B 601 (-4.3A)","0.65A","5mo4A-4xeyB:28.4","5mo4A-4xeyB:80.73"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"VAL B 275;ALA B 288;LYS B 290;ILE B 332;THR B 334;GLY B 340;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.60A","5p9iA-4xeyB:25.2","5p9iA-4xeyB:35.24"],["5TE0_A_XINA401_1","AP2-ASSOCIATED PROTEIN KINASE 1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"ALA B 288;MET B 309;VAL B 318;PHE B 336;GLY B 340;LEU B 389","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.58A","5te0A-4xeyB:24.0","5te0A-4xeyB:24.34"],["5ZV2_A_LEVA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",6,"LEU B 267;VAL B 275;ALA B 288;MET B 309;GLY B 340;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-3.5A)","0.77A","5zv2A-4xeyB:31.7","5zv2A-4xeyB:13.85"],["6BSD_A_1N1A901_0","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"VAL B 275;ALA B 288;MET B 309;THR B 334;MET B 337;GLY B 340;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.57A","6bsdA-4xeyB:24.3","6bsdA-4xeyB:12.40"],["6FNM_A_1N1A1001_1","-","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;LYS B 290;ILE B 332;THR B 334;MET B 337;GLY B 340;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.43A","6fnmA-4xeyB:27.1","6fnmA-4xeyB:32.10"],["6HCX_A_ZMRA519_1","NEURAMINIDASE","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",3,"TRP B 280;ILE B 333;GLU B 255","None","0.81A","6hcxA-4xeyB:undetectable","6hcxA-4xeyB:10.18"],["6HD4_A_STIA604_0","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;LYS B 290;MET B 309;ILE B 312;VAL B 318;ILE B 332;THR B 334","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A)","0.67A","6hd4A-4xeyB:27.9","6hd4A-4xeyB:40.64"],["6HD4_A_STIA604_0","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;ILE B 332;THR B 334;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.75A","6hd4A-4xeyB:27.9","6hd4A-4xeyB:40.64"],["6HD4_A_STIA604_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"VAL B 308;PHE B 336;MET B 337;GLY B 340","None;1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A)","0.35A","6hd4A-4xeyB:27.9","6hd4A-4xeyB:40.64"],["6HD4_B_STIB602_0","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"VAL B 275;ALA B 288;LYS B 290;MET B 309;ILE B 312;VAL B 318;ILE B 332;THR B 334","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A)","0.73A","6hd4B-4xeyB:34.1","6hd4B-4xeyB:40.64"],["6HD4_B_STIB602_0","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;ILE B 332;THR B 334;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.74A","6hd4B-4xeyB:34.1","6hd4B-4xeyB:40.64"],["6HD4_B_STIB602_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",5,"LEU B 267;VAL B 308;PHE B 336;MET B 337;GLY B 340","1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A)","0.74A","6hd4B-4xeyB:34.1","6hd4B-4xeyB:40.64"],["6HD6_A_STIA603_0","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",7,"VAL B 275;ALA B 288;LYS B 290;MET B 309;VAL B 318;ILE B 332;THR B 334","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A)","0.62A","6hd6A-4xeyB:34.3","6hd6A-4xeyB:40.64"],["6HD6_A_STIA603_0","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"VAL B 275;ALA B 288;MET B 309;VAL B 318;ILE B 332;THR B 334;PHE B 336;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);1N1 B 601 ( 4.3A);1N1 B 601 (-4.1A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.63A","6hd6A-4xeyB:34.3","6hd6A-4xeyB:40.64"],["6HD6_A_STIA603_1","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",4,"LEU B 267;ILE B 312;MET B 337;GLY B 340","1N1 B 601 (-3.7A);None;None;1N1 B 601 (-3.5A)","0.98A","6hd6A-4xeyB:34.3","6hd6A-4xeyB:40.64"],["6HD6_B_STIB601_0","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",8,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;MET B 309;ILE B 312;VAL B 318;THR B 334","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A)","0.83A","6hd6B-4xeyB:34.1","6hd6B-4xeyB:40.64"],["6HD6_B_STIB601_0","TYROSINE-PROTEIN KINASE ABL1","4xey","TYROSINE-PROTEIN KINASE ABL1","Homo sapiens",9,"LEU B 267;VAL B 275;ALA B 288;MET B 309;ILE B 312;VAL B 318;THR B 334;PHE B 336;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-4.3A)","0.83A","6hd6B-4xeyB:34.1","6hd6B-4xeyB:40.64"]]